Biocept, Inc.
BIOC
BIOC was delisted on the 24th of October, 2023.
21 hedge funds and large institutions have $6.76M invested in Biocept, Inc. in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 6 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
1.48% more ownership
Funds ownership: 10.56% → 12.04% (+1.5%)
5% less funds holding
Funds holding: 22 → 21 (-1)
6% less capital invested
Capital invested by funds: $7.21M → $6.76M (-$446K)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
67% less call options, than puts
Call options by funds: $428K | Put options by funds: $1.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$802K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$507K |
| 3 |
State Street
Boston,
Massachusetts
|
+$171K |
| 4 |
VF
Virtu Financial
New York
|
+$85.7K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$83.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Belvedere Trading
Chicago,
Illinois
|
-$384K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$269K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$136K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$60K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$52K |
BIOC Hedge Fund Activity: Q2 2021 in Review
21 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q2 2021, worth a combined $6.76M — down 6.2% from $7.21M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BIOC and 5 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 7 added.
The largest buyer was Morgan Stanley, adding an estimated $802K. The largest seller was Belvedere Trading, exiting entirely with an estimated $384K sold.
- 21 institutional investors held Biocept, Inc. (BIOC) as of Q2 2021, down from 22 in Q1 2021.
- Funds reported $6.76M of Biocept, Inc. stock for Q2 2021, down 6.2% quarter-over-quarter.
- 5 funds opened new Biocept, Inc. positions in Q2 2021 and 6 closed out, a net change of -1 holder.
- The largest Biocept, Inc. buyer in Q2 2021 was Morgan Stanley, an estimated $802K added.
- The largest Biocept, Inc. seller in Q2 2021 was Belvedere Trading, an estimated $384K sold.
Based on aggregated 13F filings for Q2 2021.